MIRM Stock Gets Stronger EPS Estimate from HC Wainwright

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright increased their Q1 2027 earnings per share estimates for Mirum Pharmaceuticals in a research report issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.09 for the quarter, up from their prior forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $195.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2027 earnings at $0.18 EPS, Q4 2027 earnings at $0.80 EPS and FY2027 earnings at $1.42 EPS.

Other equities analysts also recently issued research reports about the company. TD Cowen cut their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $142.56.

Mirum Pharmaceuticals Stock Down 0.5%

Mirum Pharmaceuticals stock opened at $87.54 on Tuesday. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The firm’s 50-day simple moving average is $99.74 and its 200 day simple moving average is $101.45. The stock has a market cap of $5.68 billion, a PE ratio of -6.02 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same quarter last year, the business posted ($0.12) earnings per share. Mirum Pharmaceuticals’s revenue was up 37.9% on a year-over-year basis.

Insider Activity

In related news, CFO Eric Bjerkholt sold 6,001 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares of the company’s stock, valued at approximately $61,600. This trade represents a 51.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 123,499 shares of company stock valued at $12,854,484 over the last quarter. Company insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MIRM. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals in the second quarter valued at approximately $513,945,000. Emerald Advisers LLC boosted its holdings in Mirum Pharmaceuticals by 8.2% in the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock valued at $36,699,000 after purchasing an additional 30,129 shares during the period. Rice Hall James & Associates LLC purchased a new stake in shares of Mirum Pharmaceuticals in the second quarter worth $12,956,000. Lisanti Capital Growth LLC bought a new stake in Mirum Pharmaceuticals during the second quarter valued at $7,410,000. Finally, Hillsdale Investment Management Inc. purchased a new position in Mirum Pharmaceuticals during the fourth quarter worth about $3,762,000.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Brelovitug succeeds in Phase III AZURE-1 study: Mirum reported that its experimental treatment met the primary endpoint in chronic hepatitis delta virus (HDV), demonstrating strong virologic response and alanine aminotransferase (ALT) normalization rates. The result supports potential regulatory filings and expands Mirum’s opportunity in a serious liver disease with limited treatment options. Mirum’s Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: FDA approves Atebrioz for FOP: The FDA approved Atebrioz for patients aged 12 and older with fibrodysplasia ossificans progressiva, an ultra-rare disorder involving abnormal bone formation. The approval, supported by PROGRESS study data showing reduced heterotopic ossification lesion volume, gives Mirum another commercial product and could diversify future revenue. FDA Approves Atebrioz for Rare Bone Disorder
• Positive Sentiment: Analysts raise targets and earnings forecasts: HC Wainwright maintained a Buy rating and lifted its price target to $195 from $140, while increasing its 2027 EPS forecast to $1.42 from $1.28. Robert W. Baird raised its target to $130 and reiterated Outperform, and Citizens increased its target to $144. The revisions suggest analysts see meaningful upside from the clinical and commercial catalysts. HC Wainwright Issues Positive Forecast for MIRM Earnings
• Neutral Sentiment: Investors may be awaiting additional detail: Although the AZURE-1 topline result was positive, further information on the data, regulatory timing and commercial potential will be important. The stock’s lower trading indicates that some investors may be taking profits or waiting for fuller trial and launch details before assigning greater value to the pipeline.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on liver and gastrointestinal disorders. The company’s medicines are intended to address serious conditions for which available treatment options are limited.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor approved in the United States for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible patients.